Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Annji Pharmaceutical CoROCO:7754 -0.70%10 PS Ratio is 718.99 as of Jul. 22, 2026, which is 2189% above its 10-year median of 31.41. GuruFocus rates ROCO:7754 with a GF Score™ of 10/100. The stock has 3 warning signs investors should review. Among 930 Biotechnology companies, Annji Pharmaceutical Co ranks worse than 95.38% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Annji Pharmaceutical Co's share price is NT$56.80.
Annji Pharmaceutical Co's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was NT$0.08. Hence, Annji Pharmaceutical Co's PS Ratio for today is 718.99.
The historical rank and industry rank for Annji Pharmaceutical Co's PS Ratio or its related term are showing as below:
ROCO:7754'
s PS Ratio Range Over the Past 10 Years
Min: 15.63 Med: 31.41 Max: 848.75
Current: 718.99
During the past 5 years, Annji Pharmaceutical Co's highest PS Ratio was 848.75. The lowest was 15.63. And the median was 31.41.
ROCO:7754's PS Ratio is ranked worse than 95.38% of 930
companies
in the Biotechnology industry
Industry Median: 9.205
vs ROCO:7754: 718.99
During the past 5 years, Annji Pharmaceutical Co's highest 3-Year average Revenue per Share Growth Rate was 308.40% per year. The lowest was 47.40% per year. And the median was 177.90% per year.
Back to Basics: PS Ratio
Annji Pharmaceutical Co (ROCO:7754) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:7754 vs VRTX, REGN, ALNY: PS Ratio Comparison
For the Biotechnology subindustry, Annji Pharmaceutical Co's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Annji Pharmaceutical Co PS Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Annji Pharmaceutical Co's PS Ratio distribution charts can be found below:
* The bar in red indicates where Annji Pharmaceutical Co's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Annji Pharmaceutical Co's Share Price of today is NT$56.80.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Annji Pharmaceutical Co's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was NT$0.08.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Annji Pharmaceutical Co (ROCO:7754) has a PS Ratio of 718.99 as of Jul. 22, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Annji Pharmaceutical Co and its competitors. This is 2189% above median its historical median of 31.41. Over the past decade, Annji Pharmaceutical Co's PS Ratio has ranged from 15.63 to 848.75. According to the industry distribution chart, Annji Pharmaceutical Co ranks #887 out of 930 companies in the Biotechnology industry, placing it in the top 95.4%.
Is Annji Pharmaceutical Co's PS Ratio too high?
Annji Pharmaceutical Co's current PS Ratio of 718.99 is 2189% above median its 10-year median of 31.41. Over the past 10 years, this metric has ranged from a low of 15.63 to a high of 848.75. The Biotechnology industry median PS Ratio is 9.21. Annji Pharmaceutical Co's value of 718.99 is 7710.9% above this industry median. Based on the distribution chart, Annji Pharmaceutical Co ranks #887 out of 930 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Annji Pharmaceutical Co has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Annji Pharmaceutical Co's PS Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Annji Pharmaceutical Co ranks #887 out of 930 companies for PS Ratio. This places Annji Pharmaceutical Co in the lower half of its industry. The industry median PS Ratio is 9.21. Annji Pharmaceutical Co's value of 718.99 is 7710.9% above this benchmark. Historically, Annji Pharmaceutical Co's own PS Ratio has ranged from 15.63 to 848.75 over the past decade. While the company's 10-year median is 31.41 vs. the industry median of 9.21, Annji Pharmaceutical Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Biotechnology company?
The median PS Ratio among Biotechnology companies is 9.21, based on 930 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Annji Pharmaceutical Co's current PS Ratio of 718.99 is 7710.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Annji Pharmaceutical Co and its competitors. For the Biotechnology industry, the median PS Ratio is 9.21 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Annji Pharmaceutical Co's current PS Ratio is 718.99, which is 2189% above median its own 10-year median of 31.41. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Annji Pharmaceutical Co stock overvalued right now?
Annji Pharmaceutical Co (ROCO:7754) has a current PS Ratio of 718.99. The current PS Ratio is 718.99, which is 2189% above median its 10-year median of 31.41 and 7710.9% above the Biotechnology industry median of 9.21. Annji Pharmaceutical Co's overall GF Score™ is 10/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Annji Pharmaceutical Co (ROCO:7754), the current PS Ratio is 718.99 as of Jul. 22, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Annji Pharmaceutical Co Ltd is an R&D based, clinical-stage new drug company dedicated to the development of first-in-class small molecules focusing on indications with highly unmet needs in the therapeutic areas of neurology, dermatology, and inflammatory disorders, including rare diseases such as idiopathic pulmonary fibrosis and Kennedy's disease, or SBMA (Spinal and bulbar muscular atrophy). Its pipeline products include AJ201, AJ302 and AJ303.
10GF Score
Get the complete analysis for ROCO:7754
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:7754 has been successfully added to your 
